EBC-46 Phase I Dose Escalation: What the First-in-Human Safety Data Showed

Phase I dose-escalation trials for EBC-46 (tigilanol tiglate) established the safety and pharmacokinetic profile of intratumoural administration. Here's what the published data showed.

Marcus Webb

14 Apr 2026 — 3 min read

The clinical development pathway for EBC-46 (tigilanol tiglate) has followed a methodical progression from preclinical studies through veterinary applications and into early-phase human trials. Understanding what the Phase I dose-escalation data actually showed — and what it did not — is essential context for anyone researching this compound.

What Phase I Trials Are Designed to Measure

Phase I clinical trials are first-in-human studies primarily designed to assess safety, tolerability, and pharmacokinetics — not efficacy. Participants typically have advanced solid tumours that have not responded to standard treatments. The primary goal is to establish the maximum tolerated dose (MTD) and characterise the dose-limiting toxicities (DLTs) that define the upper boundary of safe dosing.

For EBC-46, Phase I trials involved intratumoural injection — the same delivery method used in the veterinary Stelfonta product. This is a critical distinction: published Phase I data reflects direct injection into accessible solid tumours, not oral supplementation. The pharmacokinetics, dose-response relationships, and safety profiles established in Phase I are specific to this administration route.

Dose Escalation Design and Findings

Phase I dose escalation follows a structured design — typically a 3+3 or accelerated titration scheme — where cohorts of participants receive progressively higher doses until dose-limiting toxicities appear or a predetermined maximum is reached. QBiotics Group, the developer of tigilanol tiglate, conducted Phase I work in patients with accessible cutaneous and subcutaneous solid tumours.

Published summaries from QBiotics indicate that intratumoural EBC-46 produced rapid and visible tumour necrosis in a significant proportion of participants, with haemorrhagic responses observable within hours of injection. This aligns with the vascular disruption mechanism characterised in preclinical models. Local injection site reactions — pain, swelling, and tissue necrosis at the injection site — were the primary adverse events observed.

Systemic adverse events in early-phase data were generally manageable, which is consistent with the localised delivery approach: intratumoural injection concentrates the drug within the tumour mass, limiting systemic exposure compared to intravenous or oral administration.

Patient Selection Criteria

Phase I trial participants typically met criteria including: histologically confirmed malignancy with at least one accessible solid tumour measurable by callipers; ECOG performance status of 0–2; adequate organ function (hepatic, renal, haematologic); and no contraindicated concurrent treatments. Participants had typically exhausted standard treatment options, making Phase I participation a rational choice within a well-managed informed consent process.

Patient selection in early-phase oncology trials is deliberately conservative — researchers want to understand the drug's profile in a relatively controlled population before expanding eligibility criteria. This is why Phase I results cannot be directly extrapolated to broader patient populations or to oral supplement consumers.

Tumour Response Observations

While Phase I is not designed to measure efficacy as a primary endpoint, observed tumour responses are recorded and reported. Phase I data for EBC-46 documented cases of complete local responses at the injection site — meaning the injected tumour lesion was eliminated — in a subset of participants. Whether systemic anti-tumour effects occurred (i.e., responses at uninjected lesions via abscopal or immune-mediated mechanisms) is a question addressed in subsequent trial phases.

Published academic literature, accessible via PubMed, includes peer-reviewed reports on EBC-46 preclinical and early clinical data. Readers seeking primary data should consult these sources directly for methodology, statistical details, and full adverse event profiles.

What Phase I Data Does and Does Not Tell Supplement Consumers

Phase I data establishes proof-of-concept safety and pharmacokinetic profiles for pharmaceutical-grade intratumoural tigilanol tiglate. It does not characterise the pharmacokinetics of oral blushwood berry extract — a different product form with different bioavailability characteristics. Supplement consumers should understand that dietary blushwood berry extract products are regulated under DSHEA as dietary supplements, not as pharmaceutical agents, and are not intended to diagnose, treat, cure, or prevent any disease.

For those considering oral blushwood berry supplements, consulting a healthcare professional familiar with the botanical literature is the appropriate starting point. Brands like Blushwood Health offer access to a naturopath consultation service to help buyers make informed decisions about supplement suitability.

Reading the EBC-46 Human Trial Readouts: What Phase I and Phase II Actually Tell Us

EBC-46 Tumour Response by Histology: Which Cancer Types Show the Most Promise in Published Data